Actis Biologics (ABPL) has acquired the cancer drug discovery assets of US-based CellPoint Diagnostics for an undisclosed amount.
ABPL and its US parent, Actis Biologics, acquired about 15 patents and related assets for the technology platform Ligand Linker Drug Delivery (LLD) system, which can revolutionise chemotherapy for cancers with specific target therapy and less toxicity.
Read the news
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment